Compare Pfizer Inc (PFE) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Pfizer Inc trades at $28.24 (market cap $158.56B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.99 (market cap $132.40B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.18% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| PFE | VIG | |
|---|---|---|
Market Cap | $158.56B | $132.40B |
Volume | 44,138,282 | 1,287,188 |
Sector | Health | — |
52-Week High | $29.02 | $246.61 |
52-Week Low | $23.67 | $210.70 |
Typical Hold Time | 158 Days | 134 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
VIG trades at $239.00, up 0.85% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its role in retirement portfolios and a 7.5% quarterly dividend increase, though year-to-date growth remains modest at 3.3%.
Outlook remains positive given VIG's quality focus and historical 10% annual returns, but risks include slow dividend growth and exclusion of high-yield stocks. The ETF suits investors seeking steady income with growth potential, though competition from SCHD and market volatility pose challenges to outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
